Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R4-RA: Rituximab versus tocilizumab in anti-TNF inadequate responders with rheumatoid arthritis
2012-002535-28Phase 4Completed
- Sponsor
- Joint Research & Development Office
- Start
- Dec 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in rheumatoid arthritis (RA) comparing MabThera initial treatment with RoActemra initial treatment (2 arms). Primary endpoint: Prediction of rituximab response by synovial B-cell signatures. Started Dec 2012; status: completed.
02
Drugs
rituximabtocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2012-002535-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002535-28.